Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Date
2008
Authors
Mellor, Howard R.
Callaghan, Richard
Journal Title
Journal ISSN
Volume Title
Publisher
S. Karger AG
Abstract
Inherent and acquired resistance pathways account for the high rate of failure in cancer chemotherapy. The mechanisms or pathways mediating resistance may be classified as pharmacokinetic (i.e. alter intratumour drug exposue) or pharmacodynamic (i.e. failure to elicit cytotoxicity). More often than not, the resistant phenotype is characterised by alterations in multiple pathways. Consequently, the pathways may act synergistically or generate a broad spectrum of resistance to anticancer drugs. There has been a great deal of systematic characterisation of drug resistance in vitro. However, translating this greater understanding into clinical efficacy has rarely been achieved. This review explores the phenomenon of drug resistance in cancer and highlights the gap between in vitro and in vivo observations. This gap presents a major obstacle in overcoming drug resistance and restoring sensitivity to chemotherapy.
Description
Keywords
Keywords: anthracycline; bleomycin; carboplatin; carmustine; cisplatin; cyclophosphamide; daunorubicin; dj 927; docetaxel; doxorubicin; elacridar; epirubicin; fluorouracil; gemcitabine; hycamptin; idarubicin; ifosfamide; irinotecan; lomeguatrib; methotrexate; mitom Anticancer drugs; Cancer chemotherapy; Drug resistance; Multidrug resistance; Pharmacodynamic resistance; Pharmacokinetic resistance
Citation
Collections
Source
Pharmacology
Type
Journal article
Book Title
Entity type
Access Statement
License Rights
DOI
10.1159/000115967
Restricted until
2037-12-31